Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom J W Huizinga

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Rheumatology|March 12, 2015
Update on autoantibodies to modified proteinsRené E M Toes, Tom J W Huizinga
Current Opinion in Rheumatology|March 12, 2015
Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases: identifying causal amino acid variants?Jurgen van Heemst, Tom J W Huizinga, Diane van der Woude, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 28, 2020
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year resultsTineke Kraaij, Eline J Arends, Laura S van Dam, et al.
Journal of Autoimmunity|April 12, 2018
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosusTineke Kraaij, Sylvia W A Kamerling, Esther N M de Rooij, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Rheumatology|March 12, 2015
Update on autoantibodies to modified proteinsRené E M Toes, Tom J W Huizinga
Current Opinion in Rheumatology|March 12, 2015
Fine-mapping the human leukocyte antigen locus in rheumatoid arthritis and other rheumatic diseases: identifying causal amino acid variants?Jurgen van Heemst, Tom J W Huizinga, Diane van der Woude, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 28, 2020
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year resultsTineke Kraaij, Eline J Arends, Laura S van Dam, et al.
Journal of Autoimmunity|April 12, 2018
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosusTineke Kraaij, Sylvia W A Kamerling, Esther N M de Rooij, et al.
Pageof 1